Every figure below is transcribed from published literature (peptideprotocolportal.com, compiled 2026-09-29). None of it is a recommendation, a protocol, or a target, and none of it was written here. Whether any of it applies to a person is a question for a licensed clinician — who this is for explains why.
What the source says not to do
Quoted word for word from the notes column. Nothing here is paraphrased, and nothing has been added.
- DO NOT inject near injury site
All 2 presentations, as reported
The source lists this compound once per vial size. All of them are shown rather than one chosen for you, because the ranges differ between them.
| Vial | Dose | Frequency | Route |
|---|---|---|---|
| 5mg/5mg | 500mcg-2mg | 5-7 days/week | SubQ/IM |
| 10mg/10mg | 500mcg-2mg | 5-7 days/week | SubQ/IM |
The source's own notes
Reproduced in full, including the parts that are description rather than caution. Trimming this column for layout would remove its harm-reduction payload.
DO NOT inject near injury site
Before anything else
A compound's paperwork is the part you can actually verify. Reading a Certificate of Analysis and what a COA cannot tell you cover both halves of that, and inspecting a vial on arrival covers what to check before a vial is opened at all.